CD8+, αβ-TCR+, and γδTCR+ cells in the recipient hematopoietic environment mediate resistance to engraftment of allogeneic donor bone marrow

Journal of Immunology

Volumn 168, Issue 4, 2002, Pages 1636-1643

  Xu, Hong ^a   Exner, Beate G ^a   Cramer, Daniel E ^a   Tanner, Michael K ^a   Mueller, Yvonne M ^a   Ildstad, Suzanne T ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG TARGETING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HISTOINCOMPATIBILITY; IMMUNOPATHOGENESIS; KNOCKOUT MOUSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; ORGAN DONOR; PHENOTYPE; PRIORITY JOURNAL; STRAIN DIFFERENCE; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION; WILD TYPE; ANIMAL; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CD8+ T LYMPHOCYTE; GENETICS; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE MUTANT; PHYSIOLOGY; SKIN TRANSPLANTATION; SPLEEN; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIGENS, CD8; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SKIN TRANSPLANTATION; SPLEEN; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION TOLERANCE; WHOLE-BODY IRRADIATION;

EID: 0037082325     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.4.1636     Document Type: Article

References (59)

1. Incidence of rejection and infection after liver transplantation as a function of the primary disease: Possible influence of alcohol and polyclonal immunoglobulins
2. Malignancy
3. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients
4. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases
5. Chronic allograft failure: The clinical problem
6. Effect of immunosuppressive therapy on graft half-life projections: The collaborative transplant study
7. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
8. Persistence of host-type hematopoiesis after allogeneic bone marrow transplantation for leukemia is significantly related to the recipient's age and/or the conditioning regimen, but it is not associated with an increased risk of relapse
9. Antiviral T cell competence and restriction specificity of mixed allogeneic (PI + P2→PI) irradiation chimeras
10. Characterization of mixed allogeneic chimeras: Immunocompetence, in vitro reactivity and genetic specificity of tolerance
11. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers
12. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: The depletion of T-cell subsets in vitro and in vivo
13. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts
14. Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: Dose and timing
15. Characterization of host lymphoid cells in antibody-facilitated bone marrow chimeras
16. The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice
17. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
18. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
19. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen
20. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach
21. + cells permits engraftment of bone marrow stem cells and tolerance induction with minimal conditioning
22. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in non-obese diabetic (NOD) mice
23. Peculiar immunobiology of bone marrow allograffs. I. Graft rejection by irradiated responder mice
24. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells
25. +cells
26. Coexpression of NKR-PI and αβ-TCR on lymphoid cells in fully xenogeneic (ratrarrow]mouse) chimeras and syngeneically reconstituted (A→A) rats
27. Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells
28. A partial conditioning strategy for achieving mixed chimerism in the rat: Tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment
29. Induction of specific tissue transplantation tolerance using fractionared total lymphoid irradiation in adult mice: Long-term survival of allogeneic bone marrow and skin grafts
30. Syngeneic and allogeneic bone marrow engraftment after total body irradiation: Dependence on dose, dose rate, and fractionation
31. Chimerism and tolerance: From free-martin cattle and neonatal mice to humans
32. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
33. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
34. + cell lines
35. Analysis of T-cell subsets in rejection of κβ mutant skin allografts differing at class I MHC
36. Effect of Lyt-2 mAb on murine skin graft survivals
37. + T cells in vivo
38. Inhibition of allograft rejection by anti-T-cell receptor-αβ monoclonal antibodies preserving resistance to bacterial infection
39. + T cells play a nonredundant role in the rejection of heart allografts in mice
40. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: Identification of host-derived antidonor allocytotoxic T lymphocytes
41. Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation
42. + T cells in respiratory virus infections
43. Biology and genetics of hybrid resistance
44. f
45. Identification of a subset of murine natural killer cells that mediates rejection of Hh-Id but not Hh-1b bone marrow grafts
46. + cells in the generation of killer activity
47. T cell-accessory cell interactions that initiate allospecific cytotoxic T lymphocyte responses: Existence of both Ia-restricted and Ia-unrestricted cellular interaction pathways
48. Properties of purified T cell subsets. I. In vitro responses to class I vs. class II H-2 alloantigens
49. Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences
50. + T cells
51. + cells into cytotoxic T cells during acute rejection of allogeneic bone marrow grafts
52. Acute rejection of murine bone marrow allografts by natural killer cells and T cells: Differences in kinetics and target antigen recognized
53. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes
54. 23 induction as an early marker of functional CD3/T cell antigen receptor triggering: Requirement for receptor cross-linking, prolonged elevation of intracellular calcium and stimulation of protein kinase
55. Quantitative and qualitative effects of cyclophosphamide administration on circulating polymorphonuclear leucocytes
56. + T cells and NK cells in irradiated mice
57. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens